<DOC>
	<DOCNO>NCT01635517</DOCNO>
	<brief_summary>The aim present study investigate prospectively clinical course outcome hospitalize heart failure patient treat tolvaptan management fluid retention serum sodium level less 140 mEq/L also analyze factor related efficacy include outcome tolvaptan therapy .</brief_summary>
	<brief_title>Efficacy Safety Tolvaptan Japanese Patients With Acute Heart Failure</brief_title>
	<detailed_description>Vasopressin mediates fluid retention heart failure . Tolvaptan , oral , nonpeptide , selective vasopressin V2-receptor antagonist , show promise management heart failure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1. hospitalized patient decompensated heart failure sign fluid retention despite use diuretic tolvaptan plan tolvaptan use 2. serum Na &lt; 140 mEq/L 3. age : &gt; = 20 year time inform consent 4. provide write informed consent . 1. hemodynamic instability 2. patient hypersensitivity tolvaptan similar compound 3. anuric patient 4. patient feel thirst difficult intake fluid 5. patient pregnant , potentially pregnant willing pregnant 6. patient take tolvaptan enrollment hospitalization 7. acute coronary syndrome 8. adrenal insufficiency 9. patient schedule undergo coronary angioplasty within study period 10. ineligible patient accord investigator 's judgment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Diuretics</keyword>
	<keyword>Vasopressins</keyword>
	<keyword>Sodium</keyword>
</DOC>